Literature DB >> 24452425

An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model.

Fatema Moni Chowdhury1, Mohammed Ziaur Rahman, Sirajul Islam Khan, Chowdhury Rafiqul Ahsan, Nils-Kåre Birkeland.   

Abstract

The environmental Escherichia albertii strain DM104, which cross-reacts serologically with Shigella dysenteriae was assessed for pathogenic properties, immunogenicity, and protective efficacy in different animal models to evaluate it as a vaccine candidate against S. dysenteriae, which causes the severe disease, shigellosis. The DM104 isolate was found to be non-invasive and did not produce any entero- or cyto-toxins. The strain also showed negative results in the mouse lethal activity assay. The non-pathogenic DM104 strain gave, however, a high protective efficacy as an ocularly administered vaccine in the guinea pig eye model against S. dysenteriae type 4 challenge. It also induced a high titer of serum IgG against S. dysenteriae type 4 whole cell lysate and lipopolysaccharide. Taken together, all these results indicate a good potential for the use of the DM104 as a live vaccine candidate against shigellosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452425     DOI: 10.1007/s00284-014-0522-y

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  27 in total

Review 1.  Pathogenesis and immunology in shigellosis: applications for vaccine development.

Authors:  T L Hale; D F Keren
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Authors:  Ryan T Ranallo; Sejal Thakkar; Qing Chen; Malabi M Venkatesan
Journal:  Vaccine       Date:  2006-12-20       Impact factor: 3.641

Review 3.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

4.  Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines.

Authors:  D M Mel; B L Arsić; B D Nikolić; M L Radovanić
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

5.  Enteropathogenicity of Aeromonas hydrophila and Plesiomonas shigelloides.

Authors:  S C Sanyal; S J Singh; P C Sen
Journal:  J Med Microbiol       Date:  1975-02       Impact factor: 2.472

6.  Molecular alteration of the 140-megadalton plasmid associated with loss of virulence and Congo red binding activity in Shigella flexneri.

Authors:  C Sasakawa; K Kamata; T Sakai; S Y Murayama; S Makino; M Yoshikawa
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

7.  Serological cross-reaction between O-antigens of Shigella dysenteriae type 4 and an environmental Escherichia albertii isolate.

Authors:  Mohammed Ziaur Rahman; Selina Akter; Nafisa Azmuda; Munawar Sultana; François-Xavier Weill; Sirajul Islam Khan; Patrick A D Grimont; Nils-Kåre Birkeland
Journal:  Curr Microbiol       Date:  2013-06-09       Impact factor: 2.188

8.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

10.  Nonimmunoglobulin fraction of human milk inhibits bacterial adhesion (hemagglutination) and enterotoxin binding of Escherichia coli and Vibrio cholerae.

Authors:  J Holmgren; A M Svennerholm; C Ahrén
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.